News from afyx therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 09, 2019, 03:00 ET AFYX Therapeutics Presents Results from Rivelin Clinical Proof of Concept Study in Patients with Vulvar Lichen Sclerosus at the 2019 European Academy of Dermatology and Venereology Congress

AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results...


Jun 24, 2019, 08:00 ET AFYX Therapeutics Closes $13 Million Convertible Loan Financing

AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced the closing ...


May 23, 2019, 08:00 ET AFYX Therapeutics Presents Framework for Patient-Reported Oral Lichen Planus Symptom Severity Measure at the 2019 American Academy of Oral Medicine Annual Conference

AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced findings...


Dec 04, 2018, 09:01 ET AFYX Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of the Rivelin Patch in Patients with Vulvar Lichen Sclerosus

AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that it has ...


Sep 27, 2018, 09:00 ET AFYX Therapeutics Presents Clinical and Preclinical Research on Rivelin Treatment for Mucosal Diseases at 14th Biennial Congress of European Association of Oral Medicine

AFYX Therapeutics (formerly known as Dermtreat), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal...